7 items found in 1 pages
TB-CHAMP, VQUIN, and the first effective treatment to prevent multidrug-resistant tuberculosis
In September 2024, the World Health Organization (WHO) released new guidance on preventative treatment for tuberculosis (TB). Thanks to new evidence from two randomised controlled clinical trials, the WHO now recommends that contacts of people with multidrug-resistant TB take six months of daily levofloxacin. In this episode of the Trial Talk podcast, we find out more about the TB-CHAMP and VQUIN trials. We also learn how the teams came together to combine their data and strengthen their evidence, using new statistical methodologies developed at the MRC Clinical Trials Unit at UCL. The episode features interviews with Anneke Hesseling, Principal Investigator for TB-CHAMP, based at Stellenbosch University, and Trinh Duong, based at the MRC CTU at UCL, the trial statistician for TB-CHAMP and lead for the combined data analysis with VQUIN.
4
9/23/2024
Careers in TB trials with Andrew Nunn and Sarah Meredith
In the first episode of our new Trial Talk series, Hanif Esmail and Conor Tweed take over the microphones to interview Andrew Nunn and Sarah Meredith, who have both recently retired from the Unit, having spent a combined total of 92 years working in the field of tuberculosis (TB). As we celebrate Andrew and Sarah’s long and accomplished careers, we’ll dive into the history of TB clinical trials and muse on the future of TB research. For more information and to access the transcript: www.mrcctu.ucl.ac.uk/news/news-stor…inical-trials/ Check out our earlier podcast episodes about TB trials, also featuring Andrew Nunn: • Trial-talk-podcast – The-stream2-trial-how-should-we-treat-multi-drug-resistant-tuberculosis • Trial-talk-podcast – Andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-1 • Trial-talk-podcast – Andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-2 For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk As a listener, you
1
1/26/2024
The STREAM2 trial: how should we treat multi-drug resistant tuberculosis?
For World TB Day, this episode explores the global burden of tuberculosis (TB) and how growing antibiotic resistance can complicate treatment options. Andrew Nunn, a Professor of Epidemiology, discusses his work on the STREAM2 trial, which investigated how treatment for multi-drug resistant TB could be shortened and made more acceptable for patients. Further information is available on the STREAM Stage 2 study page at www.mrcctu.ac.uk and results from STREAM2 are published open access in The Lancet.
6
3/23/2023
Prof Pam Sonnenberg's inaugural lecture: "Conceiving, mutating and mating ideas"
As a clinically-trained academic in public health and infectious disease epidemiology, Prof Sonnenberg’s research career has focused on areas of public health priority: TB/HIV, sexual health and STIs. In her Inaugural Lecture, Pam sheds light on her journey from a South African medical student to a leader of multi-disciplinary research teams, with the consistent aim of making a difference.
337
11/4/2019
SABC TV coverage of the Africa Health Research Institute's 'Vukuzazi' programme
Vukuzazi is a population-based health ‘omics study. Designed to investigate genetic and acquired drivers of health and disease, Vukuzazi will define individual phenotypes using community-based health screening for HIV, TB and non-communicable diseases and collect biosamples to support genomic and transcriptomic study in a population of 30 000 people in the uMkhanyakude district of KwaZulu-Natal.
203
11/30/2018
Gerald Friedland - Confronting HIV and TB 6th Nov 2017
Gerald Friedland Professor Emeritus of and Senior Research Scientist in Medicine (Infectious Diseases); Professor Emeritus of Medicine and Epidemiology and Public Health; Senior Research Scientiist, Yale
457
11/10/2017